The Role of ATPase in the Development of Idiopathic Pulmonary Arterial Hypertension in Broilers by Worley, Jessica
University of Arkansas, Fayetteville
ScholarWorks@UARK
Biological Sciences Undergraduate Honors Theses Biological Sciences
12-2011
The Role of ATPase in the Development of
Idiopathic Pulmonary Arterial Hypertension in
Broilers
Jessica Worley
University of Arkansas, Fayetteville
Follow this and additional works at: http://scholarworks.uark.edu/biscuht
This Thesis is brought to you for free and open access by the Biological Sciences at ScholarWorks@UARK. It has been accepted for inclusion in
Biological Sciences Undergraduate Honors Theses by an authorized administrator of ScholarWorks@UARK. For more information, please contact
scholar@uark.edu.
Recommended Citation
Worley, Jessica, "The Role of ATPase in the Development of Idiopathic Pulmonary Arterial Hypertension in Broilers" (2011).
Biological Sciences Undergraduate Honors Theses. 2.
http://scholarworks.uark.edu/biscuht/2
The Role of ATPase in the 
Development of Idiopathic Pulmonary 
Arterial Hypertension in Broilers  
 
 
 
 
 
An Honors Thesis submitted in partial 
fulfillment of the requirements for Honors 
Studies in Biology 
 
 
 
 
 
By 
 
 
Jessica L. Worley 
 
 
 
 
 
 
 
 
2011 
Biology 
J. William Fulbright College of Arts and Sciences 
The University of Arkansas 
 2 
Acknowledgements  
 
 
 
 
 
This thesis would not have been possible without the guidance and patience of Dr. Heidi 
Kluess, Jesse Stafford, Kirk Evanson, and Audrey Stone.  
 3 
Table of Contents 
 
 
 
Chapter 1: 
Introduction………………………………………………………………………..4 
 
Chapter 2:  
Literature Review………..………………..……………………………………….8 
 
Chapter 3: 
Methodology………………………………………………………………………24 
 
Chapter 4: 
Results……………………………………………………………………………..29 
 
Chapter 5: 
Discussion…………………………………………………………………….…...33 
 
References ………………………………..……………………………………….39 
  
 
 
 
 4 
Chapter 1: 
INTRODUCTION 
Idiopathic pulmonary arterial hypertension, formerly known as primary 
pulmonary hypertension, is a rare, incurable, fatal disease of unknown cause (Naeiji, 
2004; MacLean, et al., 2000; Wideman and Hamal, 2011; Xu, et al., 2007; Giad and 
Saleh, 1995).  Each year, two new patients per million in the population are diagnosed 
with idiopathic pulmonary arterial hypertension.  Patients rarely seek medical care in the 
early stages of the disease because they are asymptomatic (Wideman and Hamal, 2011).  
Once symptoms begin and patients are diagnosed, there are relatively few treatment 
options available.  Roughly two to eight years after diagnosis, the disease progresses to 
right sided congestive heart failure and death (Runo and Lloyd, 2003; Cogolludo et al., 
2006; Wideman and Hamal, 2011).  
Idiopathic pulmonary arterial hypertension is characterized by increased 
pulmonary arterial pressure and pulmonary vascular resistance resulting from vascular 
remodeling and excess vasoconstriction, leading to the formation of plexiform lesions 
that occlude the pulmonary arterioles (Cogolludo et al., 2006; Eddahibi et al., 2006; 
Eddahibi et al., 2001; Marcos et al., 2004; Morrell et al., 2009; Xu et al., 2007; Wideman 
and Hamal, 2011; MacLean et al., 2000; Chapman and Wideman, 2000; Wideman et al., 
2007; Burnstock, 1998; Lorenzi, Anthony, and Wideman, 2008; Humbert et al., 2004; 
Giad and Saleh, 1995; Zhang et al., 2004; Budhiraja, Tuder, and Hassoun, 2004; Voelkel 
and Tuder, 1997).  These plexiform lesions are found in the lungs of approximately 80% 
of patients diagnosed with severe idiopathic pulmonary arterial hypertension (Wideman 
and Hamal, 2011).   
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Research on idiopathic pulmonary arterial hypertension has been hindered due to 
the previous lack of a model that spontaneously develops plexiform lesions (Wideman 
and Hamal, 2011; Humbert et al., 2004).  However, broiler chickens bred for rapid 
growth and meat production have been found to spontaneously develop plexogenic 
arteriopathy, pulmonary vascular resistances, and pulmonary arterial pressures similar to 
those in humans with idiopathic pulmonary arterial hypertension (Wideman et al., 2007; 
Wideman and Hamal, 2011).   
Research using chicken and mammalian models has found that increased levels of 
serotonin, a potent vasoconstrictor, act on pulmonary arterial smooth muscle cells and the 
endothelium to lead to cell proliferation and increased vasoconstriction, contributing to 
the elevated pulmonary vascular resistance characteristic of idiopathic pulmonary arterial 
hypertension (Wideman and Hamal, 2011; Herve et al., 1995; Cogolludo et al., 2006).  
Pilot data from Dr. Wideman’s lab has demonstrated that the main sites of increased 
pulmonary vascular resistance in the vasculature of broiler lungs reside in the arterioles 
of the lung (Chapman and Wideman, 2001).  More specifically, pilot data from Dr. 
Kluess’ lab suggests that serotonin constricts these 1A and the 2A arterioles in the 
chicken lung, implying their role in increasing pulmonary vascular resistance.  
Furthermore, recent evidence implies that serotonin may interact with the purinergic P2 
receptor for adenosine tri-phosphate (ATP) leading to excessive vasoconstriction 
(Dergachevea et al., 2008).  These P2 receptors normally respond to ATP by causing 
vasoconstriction in the pulmonary arterial smooth muscle cells (Burnstock, 2002).  
However, the presence of such receptors in pulmonary vasculature of broilers has not yet 
been confirmed.  
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This study is part of a larger project with the overall purpose to elucidate 
mechanisms causing increased arteriole resistance in broilers susceptible to pulmonary 
arterial hypertension, so as better to understand the mechanisms leading to plexogenic 
arteriopathy in broilers and in humans.  This will be accomplished through the 
manipulation of the amount of tryptophan, a rate limiting, essential amino acid precursor 
to the development of serotonin, in the diets of broilers susceptible to idiopathic 
pulmonary arterial hypertension (Corzo, et al., 2005; Morrel et al., 2009).  It is expected 
that the broilers with the diet excess in tryptophan will develop more severe idiopathic 
pulmonary arterial hypertension than the control group due to increased pulmonary 
arterial pressure and pulmonary vascular resistance due to excess serotonin in circulation.  
As a part of this larger project, the goal of this study is to assess the ATPase 
activity in the vascular walls of the pulmonary artery, 1A arteriole, and 2A arteriole of 
the broiler lung.  Essentially, ATPase activity modulates the amount of vasoconstriction 
through the regulation of the amount of ATP acting on the outside wall of pulmonary 
vasculature.  By breaking down ATP and preventing it from binding to the receptors on 
the vascular walls of pulmonary arterial smooth muscle cells, the vasoconstrictive effects 
of ATP are curbed.  Further acting to curb the vasoconstriction, the breakdown products 
of ATP act to enhance vasodilatation.  It is hypothesized that broilers on a diet of high 
tryptophan will have a worse case of pulmonary hypertension than those in the control 
group due to increased vasoconstriction leading to higher pulmonary arterial pressures 
and pulmonary vascular resistances.  This increased vasoconstriction is possibly due to 
increased levels of serotonin in circulation, as well as lower ATPase activity.  Therefore, 
it is hypothesized that the broilers fed the diet with high levels of tryptophan will have 
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lower ATPase activity associated with a worsening case of pulmonary hypertension. 
Whereas those on the control diet are hypothesized to have higher ATPase activity than 
those on the high tryptophan diet.   
With respect to the vessels being examined, this study will also attempt to discern 
differences in ATPase activity between the 1A arteriole, 2A arteriole, and the pulmonary 
artery.  Previous research has implicated vessel size as an important component of 
constriction; the smaller the vessel, the larger the purinergic component of constriction 
(Gitterman and Evans, 2009).  Because ATP acts on purinergic receptors in the 
pulmonary vasculature, it is hypothesized that because they are smaller vessels, 
vasoconstriction will be higher in the arterioles, thus, leading to enhanced pulmonary 
arterial pressures and pulmonary vascular resistances.  It is this increased stress that 
triggers the release of ATPase (Yegutkin et. al., 2009).  Consequently, it is hypothesized 
that this higher amount of vasoconstriction in the smaller vessels correlates to increased 
ATPase activity in response to the stress.  Therefore, the arterioles are hypothesized to 
have higher ATPase activity than the larger pulmonary arteries.    
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Chapter 2: 
LITERATURE REVIEW 
Plexogenic Arteriopathy   
The role of the endothelia in the vascular pathology of idiopathic pulmonary 
arterial hypertension is poorly understood.  It has been identified that plexiform lesions 
are composed of aggregates of these endothelial cells (pulmonary arterial smooth muscle 
cells) and platelets (Tuder et al., 2009; Wideman and Hamal, 2011).  In advanced stages 
of idiopathic pulmonary arterial hypertension, the plexiform lesions (plexogenic 
arteriopathy) develop in the endothelia of small arterioles downstream from branching 
points in lung vasculature (Wideman and Hamal, 2011; Tuder et al., 2009; Humbert, et 
al., 2004).  It is postulated that as a consequence of increased pulmonary arterial pressure, 
localized turbulent blood flow causes shear stress, resulting in damage to the endothelium 
of small arterioles (Wideman and Hamal, 2011).  This damage is believed to initiate 
disordered endothelial cell proliferation (Tuder et al., 2009; Humbert et al., 2004).  This 
endothelial cell growth causes both the thickening and muscularization of the walls of 
pulmonary arterioles, as well as narrowing of the pulmonary artery lumen, effectively 
occluding the flow of blood through them (MacLean et al., 2000; Voelkel and Tuder, 
1997; Giad and Saleh, 1995; Humbert et al., 2004).  Overall, it is this vascular 
remodeling—the hyperplasia of pulmonary arterial smooth muscle cells and the medial 
hypertrophy of pulmonary arteries—that is the main underlying pathological change in 
idiopathic pulmonary arterial hypertension (Eddahibi et al., 2006; Eddahibi and Adnot, 
2001; Marcos et al., 2004; Wideman and Hamal, 2011; Humbert et al., 2004).   
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The aggregates of endothelial cells and platelets build up and ultimately block the 
small pulmonary arterioles (Eddahibi et al., 2006; Marcos et al., 2004).  The blood flow 
that would usually be directed through these blocked vessels must be pushed through the 
remaining vessels that are only partially occluded or unaffected by the proliferation of 
endothelia cells.  Because the heart must pump blood through less pulmonary vasculature 
when the vessels are fully blocked, the cardiac output increases to make up for these 
anatomical inadequacies of pulmonary vascular capacity (Wideman et al., 2007).  Also, 
because the resistance to flow through a blood vessel is primarily determined by the 
radius of that vessel, when blood is pumped through occluded vessels with decreased 
luminal radii, the cardiac output must compensate for the increased resistance (Wideman 
et al., 2007).  Essentially, this causes an increase in pulmonary vascular resistance and 
pulmonary arterial pressure, where pulmonary arterial pressure is equal to cardiac output 
multiplied by pulmonary vascular resistance (Zhang et al., 2004; Wideman et al., 2007).   
When both pulmonary vascular resistance and cardiac output increase, the 
pulmonary arterial pressure is increased by 10 to 15 mmHg up to a characteristic level for 
idiopathic pulmonary arterial hypertension greater than or equal to 25 mmHg at rest in 
the absence of other chronic lung or heart diseases (MacLean et al., 2000; Wideman and 
Hamal, 2011).  Because the same amount of blood is being pumped through less 
vasculature at faster rates, a diffusion limitation occurs.  When the erythrocytes (red 
blood cells) are forced to flow too rapidly past the pulmonary gas exchange surfaces in 
the lungs, full blood gas exchange of O2 and CO2 is not permitted (Wideman et al., 2007; 
Wideman and Tackett, 1999).  This diffusion limitation creates the development of 
systemic arterial hypoxemia (Chapman and Wideman, 2000; MacLean et al., 2000).  This 
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leads to hypoxic pulmonary vasoconstriction in the pulmonary arteries, which enhances 
the resistance in the vessels and causes increased shear stress on the vasculature 
(MacLean et al., 2000; Burnstock, 1998).  Another contributor to idiopathic pulmonary 
arterial hypertension, is platelet dysfunction caused by the previously described vascular 
abnormalities such as hyperplasia of pulmonary arterial smooth muscle cells and medial 
hypertrophy of pulmonary arterioles.  The shear stresses lead to the increased release of 
vasoactive and mitogenic mediators such as serotonin, a potent vasoconstrictor (Humbert 
et al., 2004).   These vasoconstrictive actions of the endothelium and platelet 
dysfunctions lead to further increased pulmonary vascular resistance (Humbert et al., 
2004).  Overall, this increased pulmonary vascular resistance and vasoconstriction over 
time impedes the functioning of the right ventricle to pump blood, leading to right 
ventricle hypertrophy and ultimately to right ventricular failure (Marcos et al., 2004; 
Chapman and Wideman, 2000).  
Vasodilator therapies have attempted to reverse this vasoconstriction, however, 
have been largely unsuccessful in reversing this cycle once the presence of plexiform 
lesions is identified (MacLean et al., 2000; Wideman and Hamal, 2011).  Once patients 
have presented with plexogenic arteriopathy, they have a poor prognosis for survival 
(Wideman and Hamal, 2011).  The normal pathophysiologial progression of idiopathic 
pulmonary arterial hypertension following the development of plexogenic arteriopathy 
includes the development of systemic arterial hypoxemia, systemic arterial hypotension 
due to reduced total peripheral resistance, regurgitation by the monocuspid right 
atrioventricular valve, cardiac decompensation, right-sided congestive heart failure, 
central venous hypertension, hepatic cirrhosis, accumulation of ascitic fluid in the 
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abdominal cavity, and eventually death (Wideman and Hamal, 2011; Chapman and 
Wideman, 2000).  Despite having general information about the pathophysiological 
progression of idiopathic pulmonary arterial hypertension, further research is needed to 
understand the vascular mechanisms behind plexogenic arteriopathy.  It is hoped that 
these research efforts will lead to better treatment solutions in the future.  Several animal 
models such as rats, guinea pigs, and dogs, have been used in the research of idiopathic 
pulmonary arterial hypertension, however advances have been hindered by the previous 
absence of a model able to spontaneously recapitulate the histology of idiopathic 
pulmonary arterial hypertension especially the presence of plexiform lesions (Wideman 
and Hamal, 2011; Humbert et al., 2004).  
Broiler Chickens as Model of Idiopathic Pulmonary Arterial Hypertension 
Unlike other animal models used previously to research idiopathic pulmonary 
arterial hypertension, broiler chickens (domestic fowl bred for meat production) 
spontaneously develop semi-occlusive endothelial cell proliferation that progresses into 
the development of plexiform lesions (Wideman and Hamal, 2011).  The two primary 
triggers of idiopathic pulmonary arterial hypertension in broilers are fast growth and cool 
temperatures (Wideman et al., 2002).  In broilers, idiopathic pulmonary arterial 
hypertension is triggered by extremely rapid early growth and limitations due to their 
developmentally immature cardiovascular and pulmonary systems (Wideman and Hamal, 
2011).  Broiler chickens grow at a maximal rate in cold temperatures, however their lungs 
remain isovolumetric due to the anatomical constraints imposed by the unchanging size 
of the rib cage despite their increased metabolic requirement for oxygen (Wideman, Erf, 
and Chapman, 2001; Wideman et al., 2002; Wideman et al., 2007).  The mismatch of 
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physical constraints with the high metabolic oxygen demands lead to increases in cardiac 
output blood levels proportional to the growth rate (Wideman, Erf, and Chapman, 2001; 
Chapman and Wideman, 2006).  An oxygen/carbon dioxide diffusion limitation arises, 
just as in human idiopathic pulmonary arterial hypertension, when red blood cells flow 
too quickly past the gas exchange sites in the pulmonary vasculature to permit the 
hemoglobin to become fully saturated with oxygen (Wideman et al., 2002).  The 
diffusion limitation leads to hypoxemia, and elevated blood pressure within the 
pulmonary circulation (Wideman et al., 2002; Wideman et al., 2007; Wideman, 2006; 
Bowen et al., 2006).  The ensuing hypoxia initiates endothelial cell dysfunction, which 
leads to proliferation and formation of plexiform lesions.  Endothelial cells are important 
regulators of vascular function, and as such, endothelial dysfunction denotes an 
imbalance in the production of vasoconstrictors versus vasodilators and activators 
(mitogens) versus inhibitors of pulmonary arterial smooth muscle cell growth and 
migration (Morrell et al. 2009).  Specifically, a sustained vasoconstriction and medial 
hypertrophy of small pulmonary arterioles related to endothelial dysfunction lead to 
chronically enhanced production of or sensitivity to endothelium pro-mitogenic 
(stimulates proliferation) vasoconstrictors such as serotonin, and reduced production of or 
sensitivity to endothelium derived anti-mitogenic vasodilators such as nitric oxide 
(Humbert et al., 2004; Wideman and Hamal, 2011).  This imbalance further causes the 
pulmonary arterial pressure and pulmonary vascular resistance to increase to levels 
characteristic of idiopathic pulmonary arterial hypertension in both humans and broilers 
(Chapman and Wideman, 2006).  
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There are several similarities between human idiopathic pulmonary arterial 
hypertension and broiler idiopathic pulmonary arterial hypertension in addition to the 
presentation of plexiform lesions and the mechanism leading to hypoxia.  Broilers exhibit 
a medial hypertrophy at branch points within the pulmonary vasculature similar to those 
locations in humans (Wideman and Hamal, 2011).  In addition, the development of 
pulmonary vascular lesions permanently obliterates small pulmonary arterioles, leading 
to reductions in the available pulmonary vasculature causing increases in pulmonary 
vascular resistance (Wideman and Hamal, 2011).  This triggers a positive feedback cycle 
in which the arteriole occlusions are progressively increasing the pulmonary vascular 
resistance, thus, increasing the right ventricular after load, causing the hypertrophied right 
ventricle to increase the pulmonary arterial pressure to push the cardiac output through 
the decreasing numbers of unobstructed pulmonary vessels (Wideman and Hamal, 2011).   
Despite the similarities between human and broiler idiopathic pulmonary arterial 
hypertension, there are also key differences.  First, unlike mammals with compensatory 
mechanisms known to reduce the pulmonary vascular resistance (such as flow dependent 
pulmonary vasodilatation, arteriole distillation, capillary distention, or the recruitment of 
un- or under-perfused vascular channels), broilers do not have similar compensatory 
mechanisms to adapt when their pulmonary vasculature is incapable of accommodating 
the required cardiac output (Wideman and Chapman, 2000).  Lacking pulmonary 
vasculature elasticity, broiler right ventricles and their pulmonary arterial pressures must 
respond to the increased cardiac output (Wideman and Chapman, 2000; Wideman and 
Hamal, 2011).  Second, as broilers and humans with the disease age, the severity of 
plexogenic arteriopathy is significantly less in broilers than in humans (Wideman and 
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Hamal, 2011).  This observation could be partially due to the early death of susceptible 
broilers with idiopathic pulmonary arterial hypertension due to terminal right-sided heart 
failure (Wideman and Hamal, 2011).  These differences would be problematic if the goal 
were to discover therapeutic treatments for humans rather than studying the mechanisms 
behind idiopathic pulmonary arterial hypertension and plexogenic arteriopathy (Wideman 
and Hamal, 2011).  
Serotonin 
Research using this broiler model and mammal models has already been 
successful in uncovering some of the mechanisms of idiopathic pulmonary arterial 
hypertension, specifically with regard to advances in understanding of the roles of 
serotonin, nitric oxide, and ATP. There has been considerable interest in the role of 
serotonin in the pathogenesis of idiopathic pulmonary arterial hypertension due to the 
formation of plexiform lesions in the small pulmonary arteries and arterioles in humans 
using serotoninergic appetite suppressant drugs (anorectic drugs, anorexigens) (Chapman 
and Wideman, 2006; Wideman et al., 2007; Wideman and Hamal, 2011).  Furthermore, 
there is an association between patients using anorexigens such as fenfluramine and 
aminorex, and the development of idiopathic pulmonary arterial hypertension (Naeiji, 
2004; Eddahibi and Adnot, 2002).  In fact, in patients who received these drugs for over a 
three-month period, there was a twenty three to thirty fold increase in the risk of 
developing idiopathic pulmonary arterial hypertension (Lawrie et al., 2005; Eddahibi and 
Adnot, 2002; Cogolludo et al., 2006).  These anorexigens stimulate serotonin release in 
the blood stream and act through interactions with the serotonin transporter located on 
pulmonary arterial smooth muscle cells (Wideman and Hamal, 2011; Cogolludo et al., 
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2006; Eddahibi and Adnot, 2002).  Because of the research done to understand the 
correlation between anorexigens and idiopathic pulmonary arterial hypertension, the roles 
and mechanisms of serotonin in sustained vasoconstriction leading to increased 
pulmonary vascular resistance and in structural remodeling associated with pulmonary 
arterial smooth muscle cell proliferation are better understood.  
In healthy broilers, serotonin is the most potent vasoconstrictor capable of 
triggering essentially instantaneous and full vasoconstriction within 30 seconds leading to 
an immediate reduction in cardiac output by 90% or more and terminal suffocation 
(Wieman and Hamal, 2011; Wideman et al., 2007).  It is mainly produced in the 
enterochromaffin cells of the intestine (MacLean et al., 2000; Eddahibi et al., 2006; 
Herve et al., 1995).  From there, serotonin is normally stored in large quantities within 
the platelets or thrombocytes (MacLean et al., 2000; Eddahibi et al., 2006).  These 
nucleated thrombocytes are equivalent to mammalian platelets and are the most 
numerous leukocytes in avian blood (Wideman and Hamal, 2011; Wideman et al., 2007).  
In idiopathic pulmonary arterial hypertension, platelets dysfunction and aggregate within 
pulmonary arteries and arterioles and their ability to store serotonin becomes impaired 
(MacLean et al., 2000; Wideman et al., 2007; Pakala et al., 1994; Herve et al., 1995; 
Chapman and Wideman, 2006). This change in capacity for serotonin may be due in part 
to the lower numbers of platelets in patients with idiopathic pulmonary arterial 
hypertension, decreased pulmonary endothelial metabolism, or due to hypoxia in the 
airways of accumulating thrombocytes (MacLean et al., 2000; Herve et al., 1995; Bowen 
et al., 2006).  This abnormal managing of serotonin causes an increased circulating level 
of serotonin (Herve et al., 1995; Humbert et al., 2004; Morrell et al., 2009; MacLean et 
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al., 2000; Naeiji, 2004; Cogolludo et al., 2006).  Another cause for an increased level of 
serotonin is a mutation in the gene encoding the bone morphogenic protein receptor 2 
found in cases of familial idiopathic pulmonary arterial hypertension (Naeiji, 2004).  This 
mutation causes an up-regulation of angiopoetin-1, which further increases the amount of 
serotonin in circulation (Naeiji, 2004).  Normally, free serotonin in the plasma is rapidly 
metabolized by the endothelial monoamine oxides enzymatic activity in the liver or the 
lungs, preventing excessive serotonin levels from entering the pulmonary bed (Herve et 
al., 1995).  However, when the amount of serotonin in the plasma overwhelms the 
metabolic capabilities to break it down, excess serotonin enters the pulmonary 
vasculature.  Once circulating in the pulmonary vasculature, serotonin targets receptors 
(specifically the serotonin1b-1d, serotonin2a, and serotonin2b receptors) on pulmonary 
arterial smooth muscle cells leading to membrane depolarization and vasoconstriction 
through the inhibition of K+ channels  (Humbert et al., 2004; Morrell et al., 2009; 
Wideman and Hamal, 2011; MacLean et al., 2000; Dergacheva et al., 2008; Naeiji, 2004; 
Cogolludo et al., 2006; Eddahibi and Adnot, 2002).  These voltage gated K+ channels 
play an essential role in regulating resting membrane potential, intracellular calcium 
concentration, and contraction of vascular smooth muscle (Cogolludo et al., 2006).  
Activation of K+ channels leads to hyperpolarization of the pulmonary arterial smooth 
mucle cells, in contrast to conditions of hypoxia and serotonin binding to receptors that 
leads to the inhibition of the K+ channel, and resulting in membrane depolarization of the 
pulmonary arterial smooth mucle cells (Cogolludo et al., 2006; Humbert et al., 2004).  
This leads to the opening of Ca2+ channels, an influx of Ca2+ into the pulmonary arterial 
smooth muscle cell, and vasoconstriction (Cogolludo et al., 2006; Humbert et al., 2004).  
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It is this direct vasoconstriction related to K+ channel blockade or increased intracellular 
Ca2+ levels in pulmonary arterial smooth muscle cells that contributes to sustained 
increases in pulmonary vascular resistance and pulmonary arterial pressure that are 
characteristic of idiopathic pulmonary arterial hypertension (Wideman and Hamal, 2011; 
Eddahibi and Adnot, 2002).  
Not only is serotonin a potent vasoconstrictor, but it is also the most potent 
mitogen of all the endothelial and platelet derived growth factors, stimulating 
proliferation of vascular endothelial and pulmonary arterial smooth muscle cells 
(Wideman and Hamal, 2011).  The mitogenic effects of serotonin require it to enter into 
pulmonary arterial smooth muscle cells through serotonin transporters (Morrell et al., 
2009).  When under hypoxic conditions characteristic of idiopathic pulmonary arterial 
hypertension, there is a 2.5 to 3 fold increase in the number and activity of these 
serotonin transporters (MacLean et al., 2000).  After binding to a serotonin receptor, the 
serotonin transporter actively takes up serotonin into the endothelium (MacLean et al., 
2000; Dergacheva et al., 2008; Naeiji, 2004; Marcos et al., 2004; Lawrie et al., 2005; 
Herve et al., 1995; Cogolludo et al., 2006).  Once serotonin enters into the pulmonary 
arterial smooth muscle cells, it causes hypertrophy and proliferation of the medial muscle 
layer in pulmonary arterioles (Wideman and Hamal, 2011; Herve et al., 1995; Cogolludo 
et al., 2006).  This medial hypertrophy of pulmonary arterioles is also enhanced by the 
decreased K+ channel activity which inhibits apoptosis (Cogolludo et al., 2006).  The 
resulting proliferation of pulmonary arterial smooth mucle cells and lack of apoptosis 
lead to the formation of plexiform lesions and result in a hypoxia that re-fuels the cycle 
(Eddahibi et al., 2006; Pakala et al., 1994; Marcos et al., 2004; Eddahibi et al., 2001).  
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Nitric Oxide 
Normally in the maintenance of pulmonary vascular tone, vasoconstriction 
imposed by serotonin is balanced by vasodilatatory effects (MacLean et al., 2000).  
Vasodilators reduce the pulmonary arterial pressure required to push the necessary 
cardiac output through the pulmonary blood vessels, thus reducing pulmonary vascular 
resistance (Wideman et al., 1994).  This reduction in pulmonary vascular resistance 
should delay the pathophysiological progression of pulmonary hypertension (Wideman et 
al., 1994).  However, idiopathic pulmonary arterial hypertension results when the 
vasoconstrictors overwhelm the dilatory effects of vasodilators such as nitric oxide 
(Chapman and Wideman, 2006).  
Nitric oxide is a potent, endothelium derived pulmonary vasodilator that is 
important in maintaining the low pressure in the normal pulmonary vasculature (Giad and 
Saleh, 1995).  It is an important vasodilatory determinant of vascular resistance and 
vascular tone through the reduction of pulmonary arterial pressure (Sprague et al., 1996; 
Xu et al., 2007).  It modulates pulmonary vasoconstriction and pulmonary hypertension 
through reducing the resistance to blood flow through lungs by relaxing vascular smooth 
muscle, modulating vasoconstrictor (serotonin) release, desensitizing endothelial 
responsiveness to vasoconstrictors, inhibiting pulmonary arterial smooth muscle cell 
proliferation and platelet aggregation in precapillary arterioles, and protecting against 
hypoxia-induced vasoconstriction (Bowen et al., 2006; Giad and Saleh, 1995; Sprague et 
al., 1996; Budhiraja, Tuder, and Hassoun, 2004; Wideman and Hamal, 2011; Wideman et 
al., 2007; Chapman and Wideman, 2006; Burnstock, 1998; Wideman et al., 1994).  In 
broilers, nitric oxide also reduces the pulmonary vascular resistance by dilating the 
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vasculature and attenuating its responsiveness to endothelium dependent vasoconstrictors 
(Bowen et al., 2006).  Nitric oxide is synthesized in the vascular endothelium by either 
constitutive (endothelial) or inductable (inflammatory) forms of nitric oxide synthase 
(Bowen et al., 2006; Sprague et al., 1996; Xu et al., 2007; Burnstock, 1998).  Whereas the 
nitric oxide synthesized by endothelial nitric oxide synthase is produced in short bursts at 
low but effective concentrations, that synthesized by inflammatory nitric oxide synthase 
is produced in high quantities over a longer period of time before biologically effective 
concentrations can be produced (Bowen et al., 2006).  Most of the nitric oxide generated 
in vivo is produced by endothelial nitric oxide synthase in response to shear stress on the 
endothelium, consequent to the increased viscosity and/or flow rate during the idiopathic 
pulmonary arterial hypertension response (Sprague et al., 1996).  Specifically, it is the 
mechanical deformation of red blood cells leading to the release of ATP that is the 
primary stimulation of nitric oxide synthesis (Sprague et al., 1996).  It is this relationship 
that results in the delivery of nitric oxide to peripheral pulmonary vasculature (Sprague et 
al., 1996).  When the diffusion limitation occurs in which hemoglobin does not fully 
acquire oxygen due to increased flow rate of blood through the pulmonary vasculature, 
hemoglobin collects nitric oxide in the lungs and delivers it to the peripheral vasculature 
thus reducing vasoconstriction (Sprague et al., 1996).  Overall, it is the release of ATP in 
response to deformation of red blood cells that is the basis for vasodilatory effects of 
nitric oxide that counteract the vasoconstrictive effects of serotonin (Sprague et al., 
1996).   
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ATP and ATPase 
ATP is a neurotransmitter as well as a nucleotide that can act both as an 
intracellular energy source and an extracellular signaling tool in blood vessels (Sprague et 
al., 2003; Zhang et al., 2004; Burnstock, 2006).  It plays a significant role in transmitting 
signals from the neuron to the smooth muscle through a purinergic signaling system (Vizi 
and Burnstock, 1988; Burnstock, 2006).  Essentially, a purinergic signaling system uses 
purine nucleotides as extracellular messengers released to mediate short term (acute) 
signaling functions in secretion, vasodilatation, and vascular tone, and long term 
(chronic) signaling functions in cell proliferation, differentiation, and death (Burnstock, 
2006; Zhang et al., 2004).  The role that ATP has on manipulating the vasculature 
depends largely on the site of release.  This is due in part to different purinergic receptors 
present in different locations in the vasculature (in pulmonary arterial smooth muscle 
cells or the endothelium) (Sprague et al., 2003; Sprague et al., 1996).  Depending on the 
site of ATP release (either luminally or abluminally), the interaction of ATP with 
receptors can result in either vasoconstriction or vasorelaxation in the pulmonary 
vasculature (Sprague et al., 2003).  Specifically, ATP released abluminally from nerve 
terminals onto pulmonary arterial smooth muscle cells would interact with P2x 
purinergetic receptors producing vasoconstriction, whereas ATP released within the 
vascular lumen (intraluminally) would interact on the P2Y receptors on the endothelial 
cells, leading to vasodilatation (Sprague et al., 2003; Sprague et al., 1996).  
ATP applied to the luminal side of a vessel is released from the red blood cells 
within the circulation (Sprague et al., 1996).  These red blood cells normally contain 
 21 
large amounts of ATP and release it in response to physiological stimuli such as 
deformation due to changes in flow rates, shear stress, or hypoxia (Sprague et al., 1996).  
When this ATP binds to the endothelial P2Y receptor, the synthesis of endothelium-
derived relaxing factors—such as nitric oxide, a vasodilator—is initiated (Sprague et al., 
1996; Sprague et al., 2003).  Red blood cells can evoke nitric oxide synthesis in the 
vascular endothelium with only millimolar amounts of ATP, making ATP a crucial 
mechanism for decreasing vascular resistance and balancing vascular tone in normal 
pulmonary vasculature (Sprague et al., 2003).  However, the red blood cells of humans 
with idiopathic pulmonary arterial hypertension fail to release ATP in response to 
mechanical deformation over successive increases in flow (Burnstock, 1998; Burnstock, 
2006).  This results in a decrease in the synthesis and production of nitric oxide, and 
thereby the excessive vasoconstriction remains unbalanced by vasorelaxation 
(vasodilatation) (Burnstock, 2006).   
Whereas ATP applied luminally to P2Y receptors causes slow vasodilatation 
through the synthesis of nitric oxide, ATP applied abluminally (extracellularly) quickly 
enhances vasoconstriction (Sprague et al., 1996; Burnstock, 2006).  Extracellular ATP is 
a potent vasoconstrictor and smooth muscle and endothelial cell mitogen (Zhang et al., 
2004).  It can be released from nerve terminals near vascular smooth muscle in vascular 
endothelial cells, damaged vessel walls, hypoxic myocardium, or aggregated platelets  
(Sprague et al., 2003).  From here, ATP acts on P2X receptors, causing an influx of Ca2+ 
which leads to a rapid vasoconstriction and increase in vascular resistance (Burnstock, 
1999; Burnstock, 2008; Sprague et al., 2003).  Like intracellular ATP responses, only 
small levels (millimolar amounts) of extracellular ATP are needed to play a significant 
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role in pulmonary arterial smooth muscle cell proliferation (Zhang  et al., 2004).  After a 
small level of extracellular ATP activates the P2x receptor on the plasma membrane of the 
pulmonary arterial smooth muscle cell, phosphorylation activates cyclic AMP response 
element binding protein, which increases the expression of canonical transient receptor 
potential, and this is what raises the Ca2+ concentration leading to pulmonary arterial 
smooth muscle cell proliferation (Zhang et al., 2004; Burnstock, 2002).  
Extracellular ATP not taken up by the purinergic receptors is rapidly metabolized 
by ecto-nucleotidases (ecto-ATPase; ATPase activity) (Vizi and Burnstock, 1988).  The 
products of ATP breakdown include adenosine di-phosphate (ADP) and a free phosphate 
ion (Pi), or adenosine mono-phosphate (AMP) and two free phosphate ions (Sprague et 
al., 2003).  Of these products, ADP is capable of activating endothelial purinergic 
receptors and causing vasodilatation, and adenosine inhibits smooth muscle cell 
proliferation (Sprague et al., 2003; Burnstock, 2002).  Some research also suggests that 
the amount of ATPase increases extracelluarlly in response to shear stress (Yegutkin et. 
al, 2009).  These effects of ATPase suggest its role as an important tool in normal 
vascular functioning to maintain the balance between vasoconstriction and vasodilatation.  
Although there is minimal research on the role of ATPase in the pathology of 
idiopathic pulmonary arterial hypertension, its increase in response to shear stress would 
suggest that under conditions of decreased vessel diameter (due to plexiform lesions) and 
increased flow resistance—characteristic of idiopathic pulmonary arterial hypertension—
extracellular ATPase would be increased.  Thus, when deformed red blood cells are 
releasing ATP intracelluarly to trigger vasodilation, extracellular ATPase is also released 
to break down ATP that would act to increase vasoconstriction.  Furthermore, the 
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products of the breakdown would act against the progression of the disease by combating 
the vasoconstrictive effects of extracellular ATP by triggering vasodilatory effects with 
ADP and act to prevent further proliferation of the endothelia.  
Wedge Pressures as a Determinant of Idiopathic Pulmonary Arterial Hypertension 
 Wedge pressures estimate the downstream pressure in the pulmonary vasculature 
(Lorenzoni et al., 2008).  These estimations are essential in differentiating between 
pulmonary venous hypertension and pulmonary arterial hypertension (Lorenzoni et al., 
2008).  Wedge pressures are found by inserting a catheter into a wing vein and advancing 
it into a pulmonary branch artery until it becomes lodged in a terminal artery (Chapman 
and Wideman, 2000).  In broilers susceptible to idiopathic pulmonary arterial 
hypertension, wedge pressures higher than the right atrial pressures but lower than the 
pulmonary arterial pressure are suggestive of excessive precapillary resistance (Chapman 
and Wideman, 2000; Lorenzoni et al., 2008; Wideman and Hamal, 2011).   
 Within the larger scope of this project, wedge pressures will be taken in the 
broilers of both the high and low tryptophan groups in order to confirm their 
susceptibility to idiopathic pulmonary arterial hypertension.  This data along with wire 
myography data (which measures vasoconstriction as a function of tension) of pulmonary 
artery, 1A and 2A pulmonary arteriole responses to ATP, and ATPase data will be useful 
in determining whether or not ATP plays an important role in the development of 
idiopathic pulmonary arterial hypertension in broilers.  The overall aim of this study is to 
learn more about the mechanisms leading to increased pulmonary arterial pressure, 
plexogenic arteriopathy, and ultimately idiopathic pulmonary arterial hypertension in 
broilers and humans.  
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Chapter 3: 
METHODOLOGY 
 The role of ATPase activity in the vascular wall was investigated through the use 
of male broilers susceptible to idiopathic pulmonary arterial hypertension as a model.  
Broilers were reared at the Poultry Environmental Research Laboratory at the University 
of Arkansas Poultry Research Farm.  They were kept in environmental chambers with 
wood shavings for litter, a constant thermoneutral chamber, rapid exchange of ambient 
air, etc.  The broilers were separated into two groups, differing only in diet.  The diets 
differed in the levels of tryptophan, a necessary precursor and rate-limiting step for the 
production of serotonin.  In the control group, broilers were provided with a commercial 
diet (Cobb-Vantress Chick Starter, Siloam Springs, Arkansas) with approximately 0.22% 
tryptophan by weight with 2.2 tryptophan/kg feed (Corzo et al., 2005).  The experimental 
group was fed the same base diet (Cobb-Vantress Chick Starter, Siloam Springs, 
Arkansas) with four times the recommended total tryptophan need supplemented in 
(0.88% by weight).  These diets were continued from day one of hatching through eight 
weeks of age (or until when euthanized). 
 At four to five weeks of age, the broilers were euthanized in order to remove the 
lungs and examine the pulmonary vasculature.  After euthanization at the University of 
Arkansas Poultry Research Farm, the lungs were put on ice and transported to the 
laboratory in the HPER, where the experiments took place.  The lungs were dissected to 
remove a portion of the pulmonary artery, 1A arteriole, and 2A arteriole (making sure to 
remove blood within the vessels).  These vessels were assessed for the activity of the 
enzymes that break down ATP (ectoATPase, ATPase).  Specifically, the amount of 
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ATPase activity was quantified through the use of a QuantiChrom ATPase Assay 
(BioAssay Systems, Hayward, California).  This ATPase Assay detected amounts of free 
phosphate ion ranging from 2 pmoles of phosphate to 2,000 pmoles of phosphate.  
Because extracellular ATP was either translocated into the endothelium or broken down 
into ADP + Pi  or AMP + PiPi,  the amount of phosphate ion was related to the ATPase 
activity.  
QuantiChrom ATPase Assay 
In a clear bottom 96-well plate, phosphate standards were prepared by using a 
premix solution of 50 µM phosphate diluted down to create eight 40 µL standard 
duplicates, ranging from 0 µM to 50µM phosphate.  A series dilution of enzyme was 
performed by setting up reaction wells with 20 µL assay buffer, 10µL 4mM ATP, and 
half of a vessel (both to create a duplicate and because the whole vessel had too much 
phosphate for the assay to quantify accurately).  Duplicates of the reaction wells were set 
up next to control wells of 20 µL assay buffer, 10 µL distilled water, and 10 µL 4mM 
ATP.  This ATP was added in order to assess the amount of ATPase activity of the 
vessels in response to the same amount of ATP (4mM ATP) per reaction well.  After the 
standard wells, reaction wells, and control wells were prepared, 200 µL QuantiChrom 
reagent was added to each well.  After a one minute of mixing on a plate shaker and 5 
minute incubation at 37°C to allow for color development, the vessels were removed with 
tweezers, labeled, and frozen in excess NaCl solution (pH 7.4).  Finally, using a 
spectrophotometer (Bio-Tek, Winooski, Vermont) set at 620nm, the absorbance was 
measured and recorded.  Using the linear regression equation from the standard curve, the 
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µM concentration of phosphate, representative of the amount of ATPase activity in each 
pulmonary artery, 1A arteriole, and 2A arteriole was calculated.   
 After the assessment of the µM concentration of phosphate ion in each of the 
three vessels for each one of 20 broiler chickens, the vessels were prepared for 
quantification of the amount of protein in the vessels.  The protein assays were necessary 
to normalize the data for the differing sizes of the vessels.   
Preparation of Vessels for Protein Assays 
The stored frozen vessels from the ATPase assay were thawed in a water bath at 
37°C for 5 minutes.  Then, each vessel was transferred into a grinding tube (one at a 
time) in 375µL NaCl solution (7.4 pH).  Using a power drill with a textured glass rod 
flared at the end to fit tightly inside of the grinding test tube, the vessels were ground 
down until the NaCl solution had no large aggregates (i.e. the vessels were ground down 
to a cellular level).  The ground vessel solution was transferred 100 µL at a time into a 
clean tube.  After three minutes of centrifugation, the vessels were frozen for further the 
protein analysis. 
Due to the size differences between the pulmonary artery and the arterioles, two 
assays had to be used to quantify the protein concentrations of each.  The Coomassie 
Protein Assay (Thermo Scientific, Waltham, Massachusetts) was used to determine the 
protein concentrations of the pulmonary arteries because of its accuracy in detecting 
higher amounts of protein (accurately measures 1 µg/mL to 1500 µg/mL protein 
concentration range), and the Micro BCA Protein Assay (Thermo Scientific, Waltham, 
Massachusetts) was used to determine the protein content in the 1A and 2A arterioles due 
to its accuracy in detecting the lower ranges of protein (accurately measures 0.5 µg/mL to 
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20 µg/mL protein concentration range).  Different assays were run on the different 
vessels because the protein concentrations of the 1A and 2A arterioles were too small to 
be detected by the Coomassie Assay, whereas the protein concentrations of the 
pulmonary arteries were too large to be detected by the Micro BCA Assay (because the 
pulmonary arteries were larger than the arterioles).  Before either assay was run on the 
vessel solution, the samples were thawed in a 37 °C water bath for 5 minutes.  
Afterwards, the samples were centrifuged for 3 minutes to allow the larger precipitants 
fall to the bottom of the vial.  It was important to only use the top supernatant as the 
sample for the protein assays.  
Coomassie Protein Assay—Pulmonary Artery  
In a clear bottom 96-well plate, nine duplicate 5 µL diluted albumin (BSA) 
standards, between 0 µg/mL and 2,000 µg/mL protein concentration were prepared using 
an albumin standard (2.0 mg/mL in a solution of 0.9% saline and 0.05% sodium azide).  
Then, 5 µL of sample (from the ground pulmonary vessel in excess NaCl solution) was 
transferred to the sample wells.   Once each standard and sample well had 5 µL of either 
standard or sample respectively, 250 µL of Coomassie Reagent was added to each well.  
After 60 seconds of mixing on a plate shaker, the absorbance was measured using a 
spectrophotometer (Bio-Tek, Winooski, Vermont) at 595 nm.  Using the regression 
equation of the standard curve, the protein concentrations of the pulmonary vessels were 
determined (µg/mL).  
MicroBCA Protein Assay—1A and 2A arterioles 
In a clear bottom 96-well plate, nine duplicate 150 µL diluted albumin (BSA) 
standards, between 0 and 200 µg/mL protein concentration were prepared using an 
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albumin standard (2.0 mg/mL in a solution of 0.9% saline and 0.05% sodium azide).  
Then, 150 µL of sample (the ground 1A arteriole or 2A arteriole solution in excess NaCl 
solution) was transferred into the sample wells.  After, 150 µL Working Reagent 
Concentrate (25:24:1, Working Reagent MA: MB: MC) was added to each well.  After 
one minute of mixing on a plate shaker, two hours of incubation at 37 °C for the color 
development, and five minutes of cool down to room temperature, the absorbance was 
measured with a spectrophotometer (Bio-Tek, Winooski, Vermont) at 562 nm.  Using the 
regression equation of the standard curve, the protein concentrations of the 1A arteriole 
and 2A arteriole vessels were determined (µg/mL).  
After the concentrations of phosphate ion (µM) and protein (µg/mL) were 
collected for each vessel of the 20 broilers, the data was normalized for vessel size 
(giving µM of phosphate/µg of protein per mL).  Once the data was normalized, 
statistical analyses were run (e.g. one way repeated measures tests).  
 29 
Chapter 4:  
RESULTS 
Effect of Diet on ATPase Activity in Vessels by Type 
 There are no statistically significant differences between the two diet groups in 
any of the vessel types.  Results did not show an effect between the diets and ATPase 
activity in the vessels (overall p=0.0797).  Upon visual inspection of Figure 1, it appears 
that high tryptophan had greater ATPase activity in the pulmonary artery; however this 
relationship was opposite in the 1A and 2A arterioles.  When analyzed alone, this flip 
flop trend has a p>0.05, suggesting that it is not a statistically supported relationship.  On 
its own, although the 2A arteriole appears to have a difference between the diets upon 
looking at Figure 1, when a pairwise comparison was run to look only at the 2A activity 
between high and low tryptophan diets, there was no statistical difference with a p value 
>0.05 (=0.0830).  
  
Figure 1: ATPase 
Activity of Vessels by 
Diet 
There is no statistical 
difference in ATPase 
activity by vessel type 
(pulmonary artery, 
pulmonary 1A arteriole, or 
pulmonary 2A arteriole) 
for either the high 
tryptophan diet group or 
the control diet group 
(n=20 for all vessel types). 
Bars indicate S.E.M.  
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ATPase Activity Vessel Comparison  
 Overall, the comparison of ATPase activity between vessel types was a 
statistically sound one (p=0.0181 for the overall test), meaning that the overall test was 
statistically significant (p<0.05).  Between vessel types, only the comparison between the 
2A arteriole and the 1A arteriole revealed a statistical difference where the 2A arteriole 
had a greater ATPase activity than the 1A arteriole (p<0.05; p=0.0165; Figure 2; *).  
There were no statistical differences between the pulmonary artery with either the 1A 
arteriole (p=0.0746) or with the 2A arteriole (p=0.1249).  
 
Phosphate Variability in Vessel Types by Diet 
 The amount of variability was examined in of the amounts of phosphate measured 
in the pulmonary arteries, 1A arterioles, and 2A arterioles in both the control and high 
tryptophan diets.  Looking at Figure 3—showing the means and outliers of each group of 
vessels by diet—it appears that the 2A arterioles of the control diet have an extremely 
Figure 2: ATPase Activity 
by Vessel Type 
There is no statistical 
difference in ATPase activity 
between the pulmonary 
arteries and either the 1A 
arterioles or the 2A arterioles 
(n=20 for all vessel types). 
However, there is a difference 
(*) between the 1A arterioles 
and 2A arterioles. Bars 
indicate S.E.M.   
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varied range.  Table 1, however, shows that the 1A arterioles of both diets have the most 
outliers statistically.  Both show the trend that the pulmonary arteries have the most 
phosphate measured, followed by the 1A arterioles and then the 2A arterioles.  Figure 3 
also shows that the outliers of the vessel types overlap into ranges indicative of different 
vessel types.  
 
Table 1: Phosphate Mean, Standard Deviation of Mean, Outliers for Vessel Types 
by Diet 
  Pulmonary 
Artery  
1A 
Arteriole 
2A 
Arteriole 
Control Diet     
 Mean 301.8 µM  188.3 µM 88.6 µM 
 Std. Dev. Of Mean 25.3 23.4 25.4 
 Number of Outliers 2 3 2 
High Tryptophan 
Diet 
    
 Mean 223.0 µM 172.2 µM 101.2 µM 
 Std. Dev. Of Mean 15.7 31.9 20.7 
 Number of Outliers 3 8 2 
 
 
 
Figure 3: Variability in 
Phosphate Measured by 
Diet and Vessel Type 
The variability of the 2A 
arterioles appears to be the 
highest, though all groups 
show some outliers. (PA = 
Pulmonary Artery; 1A = 
1A arteriole; 2A = 2A 
arteriole).   
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Protein Variability in Vessel Types by Diet 
 The amount of variability in the protein measured in each vessel type by diet is 
shown in both Figure 4 and Table 2.  Figure 4 shows that the range of protein measured 
in the control pulmonary arteries is the largest.  Although Table 2 shows that both the 1A 
and 2A arterioles in the control diets have the most outliers, they are shown in the box-
whisper figure to have a smaller range than the pulmonary arteries.  Both the table and 
figure show the trend of decreasing protein concentration from the pulmonary arteries to 
the 1A arterioles and then the 2A arterioles.  This suggests that the pulmonary arteries are 
the largest and the 2A arterioles are the smallest.  
 
Table 2: Protein Mean, Standard Deviation of Mean, Outliers for Vessel Types by 
Diet 
  Pulmonary 
Artery  
1A 
Arteriole 
2A 
Arteriole 
Control Diet     
 Mean 116.3 µg 63.4 µg 13.7 µg 
 Std. Dev. Of Mean 31.8 14.7 3.3 
 Number of Outliers 1 4 4 
High Tryptophan 
Diet 
    
 Mean 53.8 µg 62.9 µg 24.2 µg 
 Std. Dev. Of Mean 13.9 14.4 4.3 
 Number of Outliers 3 2 2 
Figure 4: Variability in 
Protein Measured by Diet 
and Vessel Type 
The variability of pulmonary 
arteries appears to be the 
highest in the control diet of 
all the groups, followed by the 
1A arterioles in the high 
tryptophan diet group. (PA = 
Pulmonary Artery; 1A = 1A 
arteriole; 2A = 2A arteriole).   
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Chapter 5: 
DISCUSSION 
The goal of this specific study was to examine the role of ATPase activity in 
different pulmonary vessels (pulmonary artery, 1A and 2A arterioles) within the lung 
vasculature of broilers susceptible to idiopathic pulmonary arterial hypertension.  
Furthermore, the effect of dietary differences was examined in relation to the ATPase 
activities of these vessels. According to this study’s results, although there is no statistical 
difference in how the diets affected ATPase activity, there was a trend reversal seen 
between the pulmonary artery and the arterioles.  The arterioles in the high tryptophan 
diet appeared to have less ATPase activity than those in the control diets.  This would 
suggest that diets higher in tryptophan would lead to a worse case of pulmonary arterial 
hypertension characterized by a lower ATPase activity.  Although this trend appeared in 
the arterioles, it was the opposite in the pulmonary artery.  Furthermore, when comparing 
ATPase activities of the different vessels without regard to the diets, a statistical 
difference was found between the ATPase activities of the 1A and 2A arterioles, but not 
between the pulmonary arteries with either of the arterioles.  These combined results may 
suggest that pulmonary arteries perhaps do not have much contribution to the 
development of idiopathic pulmonary arterial hypertension.  The difference found 
between the 1A and 2A arterioles was interesting because there was more ATPase 
activity in the 2A arterioles.  This may have been due to their smaller anatomy than the 
1A arterioles, causing more ATPase activity due to the shear stress caused by the 
movement of fluid through a smaller diameter.  On the other hand, it may also suggest 
that they were breaking down ATP in greater concentrations than the 1A arterioles.  
 34 
Perhaps this is an adapted mechanism to prevent increases in pulmonary arterial pressure 
in the smaller vasculature through a higher metabolism of ATP.   
With regard to the larger study, vascular functioning data further suggest that 
pulmonary arteries perhaps do not have much contribution to the increased pulmonary 
arterial pressure and pulmonary vascular resistance related to the development of 
idiopathic pulmonary arterial hypertension.  Specifically, their lack of vasoconstriction to 
stimulation by ATP suggests the lack of purinergic receptors or lack of sensitivity to ATP 
acting on the vascular walls.  In contrast, the wire myography data showed increased 
vasoconstriction due to ATP in both the 1A and 2A arterioles regardless of feed type, 
possibly implicating the presence of purinergic receptors.  Specific to the 1A arterioles, 
the higher levels of vasoconstriction along with a decreased ATPase activity compared to 
the 2A arterioles further implicate the presence of these purinergic receptors.  This is 
because in order to have a high level of vasoconstriction less ATP needs to be broken 
down by ATPase so it can act on the vascular walls of pulmonary smooth muscle cells.  
This may also suggest that the 1A arterioles play an important role in the development of 
increased pulmonary arterial pressure and pulmonary vascular resistance.  This is an 
interesting contrast to the 2A arteriole situation that has more ATPase activity and less 
contraction than the 1A arterioles.  Less contraction caused by higher ATPase activity 
prevents more ATP from binding and causing vasoconstrictive effects.  It may be 
possible that this increased ATPase activity is a preventative measure used by 2A 
arterioles to avoid excessive pulmonary arterial pressure and pulmonary vascular 
resistance leading to pulmonary hypertension.  Perhaps because the 2A arterioles are 
anatomically smaller than the 1A arterioles, they have increased metabolism of 
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extracellular ATP as a means to prevent vasoconstriction in this smaller vessel.  This may 
be a mechanism acting to prevent excessive constriction in the smaller vessels within the 
pulmonary vasculature in order to be proactive against the effects of pulmonary 
hypertension.  The differences between the 1A and 2A arterioles may be due to different 
receptor responsiveness or different mechanisms of the use of ATP.  Overall however, 
the difference between them may implicate that the 1A arterioles play a more important 
function in the development of pulmonary hypertension than the 2A arterioles. 
In order to make clear that these broilers had developed pulmonary hypertension 
or were susceptible to pulmonary hypertension, wedge pressures were measured as part 
of the larger project.  They were able to detect the earliest changes associated with 
pulmonary hypertension through the direct measurement of pulmonary arterial pressure 
(Lorenzi, Anthony, and Wideman, 2008).  Data collected indicated that broilers in the 
high tryptophan group were more susceptible to idiopathic pulmonary arterial 
hypertension (due to increases in pulmonary arterial pressure) than those in the control 
group.  These results may suggest that the broilers fed higher levels of tryptophan 
synthesized more serotonin, which in turn, caused more vasoconstriction and higher 
pulmonary arterial pressures than in the control group.  This also supports the hypothesis 
that higher tryptophan leads to a worse case of idiopathic pulmonary arterial 
hypertension.  However, although all broilers in the high tryptophan diet group had 
higher pulmonary arterial pressures than those in the control group, not all met the 
clinical level of >25mmHg indicative of idiopathic pulmonary hypertension.  Regardless, 
broilers with high pulmonary arterial pressures had low wedge pressures, confirming the 
upstream, precapillary vasoconstrictions characteristic of pulmonary arterial 
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hypertension, as opposed to pulmonary venous hypertension (Chapman and Wideman, 
2000; Wideman and Hamal, 2011).  Though not all of the broilers developed high 
pulmonary arterial pressure, the wedge pressures confirmed that these broilers were 
susceptible to idiopathic pulmonary arterial hypertension in accordance with previous 
research.  This wedge pressure data further enhances the trend seen in the arterioles of the 
high tryptophan animals.   Less ATPase activity in the arterioles further implies a more 
severe case of hypertension.  
Limitations and Variations in Data  
Despite revealing a possible important mechanism leading to increased arteriolar 
vascular resistance and eventual development of idiopathic pulmonary arterial 
hypertension in broilers, there were some limitations to this research project.  In the 
QuantiChrom ATPase Assay, the vessels had to be split in half due to overdevelopment 
of the reagent in a short period of time, possibly leading to the release of excess ATP 
from the endothelia.  Furthermore, although the goal was to identify role of ATPase 
activity on the surface of pulmonary arterial smooth muscle cells, because the endothelia 
of the vessels was not removed, its role in the production of ATP cannot be ruled out.  
This excess ATP would have added to the amount of ATP in the assay, which when 
broken down and measured by its phosphate, would inaccurately represent the amount of 
ATPase activity present.   However, previous research suggests that these amounts of 
ATP by the endothelia would be minimal (Sprague et al., 2003).  Furthermore, there were 
challenges imposed by the vessels themselves.  For example, there was much variability 
among the vessels, especially the 1A arterioles, possibly leading to decreased accuracy in 
statistical tests (many p>0.05).  Some vessels also had blood still attached, despite 
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attempts to remove it all before assays were run.  This blood could have led to increases 
in the amount of ATP being broken down by ATPase activity, thus increasing the 
measured phosphate levels.  
All three vessel types were initially analyzed for protein content using the 
Coomassie Assay, however, the protein concentrations of some 1A arterioles and all of 
the 2A arterioles were too small to be detected by this assay.  Therefore, the arterioles 
were analyzed for protein using the Micro BCA Protein Assay, which is more sensitive to 
lower levels of protein.  The reason that the pulmonary arteries were not assessed using 
the Micro BCA Assay, was that their sample ran out due to the larger required amounts 
of sample to run the Coomassie Assay in duplicates.  Unfortunately, adequate samples of 
the pulmonary artery solutions were not available to run the MicroBCA protein assay. 
The problem with using different assays is that there is not continuity in the means of 
measurement, reducing result credibility.  Finally, excess blood remaining in or on the 
vessels could have increased the amount of protein, thus misrepresenting 
phosphate/protein levels and therefore ATPase activity within the vessels.  An attempt 
was made to remove all of the excess blood from the vessels before any assays occurred.  
 There was a lot of variation between the vessels themselves.  Such variation likely 
took away from statistical validity of many of the tests.  Some possible sources of 
variation in the vessels, especially in the 1A and 2A arterioles, occurred anatomically.  
For example, as the broilers aged their vessels gained fat pockets that caused the vessels 
to float and retain more blood—thus altering the amount of protein and possibly 
phosphate measured in the assays leading to outliers and a large range of data for each 
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vessel type.  It was likely a combination of both variation in the phosphate and protein 
data that affected the lack of statistical validity to differences between vessel type.   
 Conclusion 
Overall, this research implicates the roles of the 1A and 2A arterioles and ATPase 
activity in the pathology of idiopathic pulmonary arterial hypertension in the broiler 
model.  Unfortunately, there is no previous research to compare this to; however, these 
results suggest an exciting new area that may be related to the development of increased 
pulmonary arterial pressure.  In the future, research should look into the mechanism 
behind ATP in the 1A and 2A arterioles, as it may be an important element in the 
development of idiopathic pulmonary arterial hypertension.  Such research is needed to 
determine whether or not ATP is acting on purinergic receptors on the walls of broiler 
pulmonary arterial smooth muscle cells or due to other mechanisms entirely.   
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